Onconetix, Inc. (ONCO)
Automate Your Wheel Strategy on ONCO
With Tiblio's Option Bot, you can configure your own wheel strategy including ONCO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ONCO
- Rev/Share 360.2082
- Book/Share 845.1341
- PB 0.0044
- Debt/Equity 2.0026
- CurrentRatio 0.1724
- ROIC -4.1385
- MktCap 1951764.0
- FreeCF/Share -1363.3912
- PFCF -0.2678
- PE -0.0004
- Debt/Assets 0.4818
- DivYield 0
- ROE -2.9356
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Onconetix, Inc. (NASDAQ: ONCO ) related to its merger with Ocuvex Therapeutics, Inc. Upon completion of the proposed transaction, each share of Ocuvex will be exchanged for a number of Onconetix shares based on a defined exchange …
Read More
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved a proposal to effect a reverse split, which was voted on at the Company's 2025 special meeting of stockholders (the “Special Meeting”) held on May 30, 2025, and that its Board of Directors (the “Board of Directors” or “Board”) approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of …
Read More
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “10-Q”) is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”).
Read More
Onco-Innovations Uplists to Cboe Canada
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
TORONTO--(BUSINESS WIRE)---- $ONCO #Cboe--Cboe Canada is pleased to announce that Onco-Innovations Limited is available for trading under the ticker symbol ONCO.
Read More
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that new clinical data of Proclarix® was presented on March 23, 2025 during the 2025 European Association of Urology (EAU) congress, which data further demonstrates the strong clinical performance of Proclarix® in a Danish cohort.
Read More
About Onconetix, Inc. (ONCO)
- IPO Date 2022-02-18
- Website https://onconetix.gcs-web.com
- Industry Biotechnology
- CEO Karina M. Fedasz
- Employees 12